Literature DB >> 20046261

All that wheezes is not asthma.

Andrew C Miller1, Rashid M Rashid, Elamin M Elamin.   

Abstract

Entities:  

Year:  2009        PMID: 20046261      PMCID: PMC2791745     

Source DB:  PubMed          Journal:  West J Emerg Med        ISSN: 1936-900X


× No keyword cloud information.
A 34-year-old African American woman presented with shortness-of-breath, wheezing, pedal edema, and a rash. On examination she had reddish-purple indurated plaques and nodules on the nasal rim and cheeks, and raised plaques on the trunk and extremities (Figures 1 and 2). Jugular venous distension, diffuse wheezing, rales, and bilateral pitting pedal edema were present. Her chest x-ray and CT scan demonstrated bilateral hilar lymphadenopathy. A 2-D echo revealed a 10% ejection fraction. Serum was ANA-negative with elevated angiotensin-converting enzyme levels and lymphocytopenia. Cutaneous biopsies showed non-caseating granulomas. The attending physician diagnosed disseminated sarcoidosis and initiated systemic steroid treatment. The patient was to have an automatic implantable cardioverter defibrillator (ICD) placed due to advanced cardiomyopathy and, as per protocol, underwent routine cardiac catheterization one day prior. The patient died post-catheterization from unstable ventricular tachycardia.
Figure 1.

Upper extremity cutaneous plaque sarcoidosis

Figure 2.

Lower extremity cutaneous sarcoidosis

This patient’s skin findings are characteristic of plaque sarcoidosis with nasal lupus pernio. This chronic granulomatous disorder is characterized by activated T-lymphocytes and macrophages and may involve any organ system. Cutaneous lesions were the first recognized manifestations of sarcoidosis.1 The ACCESS study characterized sarcoidosis in 736 patients in the U.S.2 Sarcoid-specific cutaneous lesions were observed in 15.9% of all sarcoid patients.2 Plaque sarcoid heralds long-standing disease, and lupus pernio is highly predictive of upper airway involvement. The ACCESS study criteria for diagnosing cardiac involvement rely on the presence of cardiomyopathy or electrocardiographic or scintigraphic abnormalities in patients with known sarcoidosis.3 Conversely, the Japanese Ministry of Health and Welfare criteria take into account symptoms, electrocardiographic, echocardiographic, and scintigraphic findings.3 Corticosteroids remain the cornerstone of treatment.1 Current guidelines for ICD implantation are the same as for those with other nonischemic cardiomyopathies.3 Emergency physicians must remember that “all that wheezes is not asthma.” Multi-system disorders such as sarcoidosis must be considered in patients with shortness-of-breath, rash, and signs of heart failure.
  3 in total

Review 1.  Hepatic, ocular, and cutaneous sarcoidosis.

Authors:  Anthony S Rose; Marcus A Tielker; Kenneth S Knox
Journal:  Clin Chest Med       Date:  2008-09       Impact factor: 2.878

2.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

Review 3.  Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis.

Authors:  Steven A Lubitz; Seth H Goldbarg; Davendra Mehta
Journal:  Prog Cardiovasc Dis       Date:  2008 Jul-Aug       Impact factor: 8.194

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.